|
Oct 16
|
Why I Keep Buying These 14 Incredible Growth Stocks
|
|
Oct 15
|
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
|
|
Oct 1
|
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
|
|
Oct 1
|
BMS and Prime ink potential $3.5bn deal to develop T cell therapies
|
|
Sep 30
|
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
|
|
Sep 30
|
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
|
|
Sep 30
|
Prime Medicine Unveils Strategically Focused Pipeline
|
|
Sep 30
|
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
|
Sep 30
|
Prime to narrow gene editing research as it strikes deal with Bristol Myers
|
|
Jun 21
|
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
|
|
May 25
|
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
|
|
May 14
|
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?
|
|
May 13
|
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
|
May 12
|
Alphabet Bought Up Two Slumping Stocks
|
|
May 11
|
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
|
|
May 10
|
Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments
|
|
May 10
|
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 8
|
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
|
|
May 3
|
What Makes Prime Medicine, Inc. (PRME) a New Buy Stock
|
|
May 1
|
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
|